<scp>EGF</scp>/<scp>EGFR</scp>‐<scp>YAP</scp>1/<scp>TEAD</scp>2 signaling upregulates <scp>STIM</scp>1 in vemurafenib resistant melanoma cells
Weiyu Bai, Chenghao Yan, Yichen Yang, Lei Sang, Qinggang Hao, Xinyi Yao, Yingru Zhang, Jia Yu, Yifan Wang, Xiaowen Li, Mingyao Meng, Jilong Yang, Junling Shen, Yan Sun, Jianwei Sun
Abstract
sensor for store-operated calcium entry and is closely associated with carcinogenesis and tumor progression. Previously, we found that STIM1 is upregulated in melanoma cells resistant to the serine/threonine-protein kinase B-raf inhibitor vemurafenib, although the mechanism underlying this upregulation is unknown. Here, we show that vemurafenib resistance upregulates STIM1 through an epidermal growth factor (EGF)/epidermal growth factor receptor (EGFR)-Yes-associated protein 1 (YAP1)/TEA domain transcription factor 2 (TEAD2) signaling axis. Vemurafenib resistance can lead to an increase in EGF and EGFR levels, causing activation of the EGFR signaling pathway, which promotes YAP1 nuclear localization to increase the expression of STIM1. Our findings not only reveal the mechanism by which vemurafenib resistance promotes STIM1 upregulation, but also provide a rationale for combined targeting of the EGF/EGFR-YAP1/TEAD2-STIM1 axis to improve the therapeutic efficacy of BRAF inhibitor in melanoma patients.